Xellia is monitoring the situation closely and has taken steps to mitigate risk and ensure effective management of its operations and resources, minimizing the potential impact of the outbreak on its supply chains and the safety of its employees.
Xellia’s Customer Service representatives have contacted customers, partners and suppliers on a case-by-case basis and will continue to provide regular updates until the public health matter subsides.
Xellia adheres to strict health and safety standards. It has dedicated Environment, Health and Safety teams present at all production sites to oversee a wide range of programs to ensure the health and safety of employees.
All work is carried out in accordance with the sanitary mitigations and precautionary principles implemented locally, regionally and nationally.
- The Danish Health Authority, for Xellia Pharmaceuticals ApS in Denmark (API and FDF principal manufacturing site)
- The Ministry of Human Capacities, for Xellia Gyógyszervegyészeti Kft. in Hungary (API manufacturing site)
- The Centers for Disease Control and Prevention (CDC) for Xellia Pharmaceuticals USA, LLC. in the United States of America (FDF packaging site)
- The National Health Commission of the People's Republic of China for Xellia (Taizhou) Pharmaceuticals Co., Ltd. (API manufacturing site)
For more detailed information on our response to the COVID-19 outbreak and specific information on our different sites and products contact us at: +1 (847)-947-0200 (for the United States of America and Canada) or at +45 32 64 55 00 (for all other countries)